WGRX Wellgistics Health (NASDAQ) earnings pre-market: $0.13 price, LOI in focus

WGRX stock is in focus pre-market as Wellgistics Health, Inc. (NASDAQ: WGRX) reports earnings today, 24 Mar 2026. We see the share price near $0.13 and heavy volume of 15,626,923 shares trading, driven by a new LOI to evaluate a $105,000,000 acquisition. The company posts negative EPS of -1.28 and a market cap near $8,675,441.00, so earnings and the LOI will determine short-term trading and strategic direction.

WGRX stock earnings snapshot

Wellgistics announces earnings pre-market on 24 Mar 2026 with the event time set for 04:00 UTC. The company shows trailing EPS of -1.28 and a TTM PE of -0.10, highlighting net losses. Investors should watch revenue beats or misses, since the firm trades at $0.126 and is highly sensitive to guidance and deal updates.

LOI acquisition news and WGRX stock reaction

Wellgistics filed a non-binding LOI to evaluate Neuritek Therapeutics, describing a potential all-stock deal valued at about $105,000,000. The LOI aims to add neuroscience research to the distribution platform and could shift margin mix. Read the company filing on the Nasdaq release and see coverage on Investing.com for market context source source.

WGRX stock financials and valuation

Wellgistics operates in Healthcare, Medical – Distribution with fragile fundamentals. Key ratios show price/sales 0.37, EV/Sales 1.42, and negative free cash flow per share of -0.15. CurrentRatio is weak at 0.09, and book value per share is -0.18, signaling balance sheet stress. These metrics frame why earnings and any transaction details matter for valuation.

Trading signals and technicals for WGRX stock

Technicals show oversold conditions: RSI 25.94 and MFI 10.24. Price trades below its 50-day average ($0.29) and 200-day average ($0.72). Volume is elevated at 15,626,923 versus average 2,303,913, showing outsized interest in pre-market. Traders should expect volatility given ADX 55.77 and wide intraday swings between $0.12 and $0.13.

Meyka AI rates WGRX with a score out of 100

Meyka AI rates WGRX with a score out of 100: 65.38 / 100, Grade B, Suggestion: HOLD. This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects recovery potential but acknowledges weak liquidity and negative EPS. These grades are not guaranteed and we are not financial advisors.

Earnings outlook, catalysts and risks for WGRX stock

Earnings will test revenue traction and margin progress after recent scaling. Key catalysts include LOI due diligence, any firm acquisition terms, and updates on DelivMeds adoption. Major risks are continued negative cash flow, low current ratio, and possible share dilution from an all-stock deal. Monitor company comments and filings through the Meyka WGRX page for updates Meyka WGRX page.

Final Thoughts

Key takeaways: WGRX stock faces a pivotal earnings release pre-market on 24 Mar 2026 while markets digest a potential Neuritek LOI. The share price is $0.126 and volume is unusually high at 15,626,923, so short-term moves may be sharp. Meyka AI’s forecast model projects a 12-month base case target of $0.40, implying 217.46% upside from $0.126, and a conservative downside scenario near $0.06. Meyka AI’s projections are model-based and not guarantees. Investors should weigh acquisition execution risk, continued negative EPS of -1.28, and weak liquidity before acting. We will update this outlook as the earnings call and any definitive acquisition terms arrive.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.